PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Cerchione, C. [1 ]
Pugliese, N. [1 ]
Marano, L. [1 ]
Cerciello, G. [1 ]
Avilia, S. [1 ]
Pane, F. [1 ]
Catalano, L. [1 ]
机构：
[1] AOU Federico II, Hematol, Naples, Italy
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1030
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [21] Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia
    Waladkhani, AR
    EUROPEAN JOURNAL OF CANCER CARE, 2004, 13 (04) : 371 - 379
  • [22] Pegfilgrastim in the primary prophylaxis of chemotherapy-induced severe neutropenia
    Olvera Alberto, Serrano
    Fernando, Alban
    Alberto, Villalobos
    Cwilich Raquel, Gerson
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (01): : 3 - 10
  • [23] The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies
    Mahtani, Reshma
    Crawford, Jeffrey
    Rifkin, Robert
    Dale, David
    Brookhart, Alan
    Gawade, Prasad
    Lawrence, Tatiana
    Balani, Rejesh
    Lyman, Gary H.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2107 - 2113
  • [25] Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
    Derek Weycker
    Xiaoyan Li
    Jacqueline Figueredo
    Rich Barron
    Spiros Tzivelekis
    May Hagiwara
    Supportive Care in Cancer, 2016, 24 : 2309 - 2316
  • [26] Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims
    Weycker, Derek
    Hanau, Ahuva
    Lonshteyn, Alexander
    Bowers, Charles
    Garawin, Tamer
    Bensink, Mark
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 725 - 730
  • [27] Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
    Weycker, Derek
    Li, Xiaoyan
    Figueredo, Jacqueline
    Barron, Rich
    Tzivelekis, Spiros
    Hagiwara, May
    SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 2309 - 2316
  • [28] Incidence of febrile neutropenia and effectiveness of pegfilgrastim prophylaxis in patients with advanced-stage solid tumors receiving chemotherapy.
    Crawford, Jeffrey
    Reiner, Maureen
    Morrow, Phuong Khanh H.
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] CarfilzomibIn Relapsed, or Relapsed and Refractory, Multiple Myeloma
    Paul L. McCormack
    Drugs, 2012, 72 : 2023 - 2032
  • [30] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    DRUGS, 2012, 72 (15) : 2023 - 2032
12345